| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20388100P | 2000-05-12 | 2000-05-12 | |
| US60/203,881 | 2000-05-12 | ||
| US22242200P | 2000-08-01 | 2000-08-01 | |
| US60/222,422 | 2000-08-01 | ||
| PCT/US2001/015423WO2001087328A2 (en) | 2000-05-12 | 2001-05-11 | Interleukin-1 inhibitors in the treatment of diseases |
| Publication Number | Publication Date |
|---|---|
| AU2001259758A1true AU2001259758A1 (en) | 2001-11-26 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001259758AAbandonedAU2001259758A1 (en) | 2000-05-12 | 2001-05-11 | Interleukin-1 inhibitors in the treatment of diseases |
| Country | Link |
|---|---|
| US (3) | US20010053764A1 (en) |
| EP (4) | EP2241328A1 (en) |
| AU (1) | AU2001259758A1 (en) |
| WO (1) | WO2001087328A2 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7091181B2 (en) | 1994-12-12 | 2006-08-15 | Omeros Corporation | Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors |
| US7811990B2 (en)* | 1998-09-25 | 2010-10-12 | Sciaticon Ab | Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus |
| SE9803710L (en) | 1998-09-25 | 2000-03-26 | A & Science Invest Ab | Use of certain substances for the treatment of nerve root damage |
| US7115557B2 (en) | 1998-09-25 | 2006-10-03 | Sciaticon Ab | Use of certain drugs for treating nerve root injury |
| US7906481B2 (en) | 1998-09-25 | 2011-03-15 | Sciaticon Ab | Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus |
| PT1129190E (en) | 1998-11-13 | 2007-08-08 | Immunex Corp | Human tslp dna and polypeptides |
| WO2003032898A2 (en) | 2001-07-23 | 2003-04-24 | Immunex Corporation | Modified human thymic stromal lymphopoietin |
| PL374118A1 (en)* | 2001-08-07 | 2005-10-03 | Immunex Corporation | Interleukin-1 receptors in the treatment of diseases |
| CA2458622A1 (en)* | 2001-08-24 | 2003-03-06 | Maine Medical Center Research Institute | Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| AU2003209150A1 (en)* | 2002-01-04 | 2003-07-24 | Combinatorx, Incorporated | Combination for the treatment of immunoinflammatory disorders and proliferative skin diseases |
| US7572770B2 (en)* | 2002-06-27 | 2009-08-11 | University Of Zurich | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| EP1608407B1 (en)* | 2003-03-20 | 2006-08-30 | Pharmacia Corporation | Dispersible formulation of an anti-inflammatory agent |
| US20050004098A1 (en)* | 2003-03-20 | 2005-01-06 | Britten Nancy Jean | Dispersible formulation of an anti-inflammatory agent |
| US20040214753A1 (en)* | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| US20050009931A1 (en)* | 2003-03-20 | 2005-01-13 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| WO2004100987A2 (en)* | 2003-05-06 | 2004-11-25 | Regeneron Pharmaceuticals, Inc. | Methods of using il-1 antagonists to treat neointimal hyperplasia |
| US20050171015A1 (en)* | 2003-10-31 | 2005-08-04 | Crabtree Gerald R. | Methods and agents for enhancing bone formation or preventing bone loss |
| CN1946734B (en) | 2004-02-26 | 2012-07-18 | 贝勒研究院 | Compositions and methods for the systemic treatment of arthritis |
| US7563804B1 (en)* | 2004-04-19 | 2009-07-21 | Hovanes John Ter-Zakarian | FMF treatment |
| MXPA06014126A (en)* | 2004-06-04 | 2007-07-18 | Regeneron Pharma | Methods of using il-1 antagonists to treat autoinflammatory disease. |
| KR20070085227A (en)* | 2004-08-09 | 2007-08-27 | 앨리오스 바이오파마 인크. | Synthetic hyperglycosylation, protease resistant polypeptide variants, oral preparations and methods using the same |
| US7597884B2 (en)* | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| AU2005277236A1 (en)* | 2004-08-20 | 2006-03-02 | Amgen Inc. | Methods and compositions for treating allergic inflammation |
| CA2583274A1 (en)* | 2004-10-05 | 2007-02-15 | Ochsner Clinic Foundation | Enhancement of b cell proliferation by il-15 |
| US20080292628A1 (en)* | 2004-10-12 | 2008-11-27 | Amprotein Corporation | Chimeric Protein |
| US20060160737A1 (en)* | 2005-01-14 | 2006-07-20 | Allen Radin | Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis |
| US8088773B2 (en)* | 2005-05-12 | 2012-01-03 | The Texas A&M University System | Therapeutic compositions and methods |
| CA2607726A1 (en)* | 2005-05-16 | 2006-11-23 | Children's Medical Center Corporation | Method of treating lymphangioleiomyomatosis (lam) |
| KR101502920B1 (en) | 2005-06-21 | 2015-03-17 | 조마 (유에스) 엘엘씨 | IL-1β Binding antibodies and fragments thereof |
| WO2007047969A2 (en)* | 2005-10-21 | 2007-04-26 | Amgen Inc. | Methods of decreasing vascular calcification using il-1 inhibitors |
| EP3332807B1 (en) | 2005-10-26 | 2023-02-22 | Novartis AG | Use of anti il-1beta antibodies |
| RU2554747C9 (en) | 2006-12-20 | 2015-10-20 | Ксома (Сша) Ллс | Method of treating il-1beta-dependent diseases |
| US8034014B2 (en) | 2007-03-06 | 2011-10-11 | Biomet Biologics, Llc | Angiogenesis initation and growth |
| US20080260820A1 (en)* | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| CA3080328C (en)* | 2007-05-29 | 2022-06-21 | Novartis Ag | New indications for anti-il-1-beta therapy |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| CA2710406A1 (en)* | 2007-09-11 | 2009-04-09 | Dorian Bevec | Use of a peptide as a therapeutic agent |
| US20100204153A1 (en)* | 2007-09-11 | 2010-08-12 | Dorian Bevec | Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| RU2010113970A (en)* | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | USE OF PHPFHLFVY PEPTIDE (RENIN INHIBITOR) AS A THERAPEUTIC |
| WO2009086003A1 (en)* | 2007-12-20 | 2009-07-09 | Xoma Technology Ltd. | Methods for the treatment of gout |
| US20090191287A1 (en)* | 2008-01-29 | 2009-07-30 | Johnson W Dudley | Mitigation of Inflammation-Related Injuries |
| EP2259774B1 (en) | 2008-02-27 | 2012-12-12 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US8753690B2 (en)* | 2008-02-27 | 2014-06-17 | Biomet Biologics, Llc | Methods and compositions for delivering interleukin-1 receptor antagonist |
| US20110189172A1 (en)* | 2008-06-06 | 2011-08-04 | Xoma Technology, Ltd. | Methods for the treatment of rheumatoid arthritis |
| US20100069343A1 (en)* | 2008-07-18 | 2010-03-18 | Andrea Vambutus | Methods of predicting steroid responsiveness with Il-1RII |
| CA2735940A1 (en) | 2008-09-05 | 2010-03-11 | Xoma Technology Ltd. | Methods for treating or preventing il-1.beta. related diseases |
| US8389474B1 (en)* | 2009-07-14 | 2013-03-05 | Alan Anson Wanderer | Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion |
| WO2011031553A2 (en) | 2009-08-27 | 2011-03-17 | Biomet Biologics, Llc | Implantable device for production of interleukin-1 receptor antagonist |
| US20110052561A1 (en)* | 2009-08-27 | 2011-03-03 | Biomet Biologics,LLC | Osteolysis treatment |
| AU2010294249A1 (en)* | 2009-09-10 | 2012-05-03 | Cytos Biotechnology Ag | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| CN101690801B (en) | 2009-10-26 | 2012-08-01 | 上海交通大学 | Application of interleukin-1 receptor antagonist and medicinal composition thereof |
| MX2012012063A (en)* | 2010-04-16 | 2013-03-21 | Medimmune Ltd | Compositions and methods for treating copd exacerbation. |
| CA2797846A1 (en) | 2010-05-07 | 2011-11-10 | Xoma Technology Ltd. | Methods for the treatment of il-1.beta. related conditions |
| EP2598526B1 (en) | 2010-07-29 | 2018-09-05 | Eleven Biotherapeutics, Inc. | Chimeric il-1 receptor type i agonists and antagonists |
| EP2611456A2 (en) | 2010-09-03 | 2013-07-10 | Biomet Biologics, LLC | Methods and compositions for delivering interleukin-1 receptor antagonist |
| MX2015012404A (en) | 2013-03-13 | 2016-02-03 | Eleven Biotherapeutics Inc | Chimeric cytokine formulations for ocular delivery. |
| US9950035B2 (en) | 2013-03-15 | 2018-04-24 | Biomet Biologics, Llc | Methods and non-immunogenic compositions for treating inflammatory disorders |
| US9758806B2 (en) | 2013-03-15 | 2017-09-12 | Biomet Biologics, Llc | Acellular compositions for treating inflammatory disorders |
| US9895418B2 (en) | 2013-03-15 | 2018-02-20 | Biomet Biologics, Llc | Treatment of peripheral vascular disease using protein solutions |
| US20140271589A1 (en) | 2013-03-15 | 2014-09-18 | Biomet Biologics, Llc | Treatment of collagen defects using protein solutions |
| US10208095B2 (en) | 2013-03-15 | 2019-02-19 | Biomet Manufacturing, Llc | Methods for making cytokine compositions from tissues using non-centrifugal methods |
| US9878011B2 (en) | 2013-03-15 | 2018-01-30 | Biomet Biologics, Llc | Treatment of inflammatory respiratory disease using biological solutions |
| US10143725B2 (en) | 2013-03-15 | 2018-12-04 | Biomet Biologics, Llc | Treatment of pain using protein solutions |
| WO2015081253A1 (en) | 2013-11-26 | 2015-06-04 | Biomet Biologics, Llc | Methods of mediating macrophage phenotypes |
| GB201412410D0 (en)* | 2014-07-11 | 2014-08-27 | Isis Innovation | Treatment |
| US10441635B2 (en) | 2014-11-10 | 2019-10-15 | Biomet Biologics, Llc | Methods of treating pain using protein solutions |
| US9763800B2 (en) | 2015-03-18 | 2017-09-19 | Biomet C. V. | Implant configured for hammertoe and small bone fixation |
| AU2020288361A1 (en)* | 2019-06-07 | 2022-02-03 | Selectimmune Pharma Ab | Treatment and diagnosis of chronic inflammatory conditions in the lower urinary tract |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6008217A (en) | 1995-12-20 | 1999-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US5196430A (en) | 1986-12-31 | 1993-03-23 | Hoechst-Roussel Pharmaceuticals Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
| US5096906A (en) | 1986-12-31 | 1992-03-17 | University Of Virginia Alumni Patents Foundation | Method of inhibiting the activity of leukocyte derived cytokines |
| US5319071A (en) | 1987-11-25 | 1994-06-07 | Immunex Corporation | Soluble interleukin-1 receptors |
| US5296592A (en)* | 1987-11-25 | 1994-03-22 | Immunex Corporation | Process for purifying interleukin-1 receptors |
| WO1989004838A1 (en)* | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
| US5081228A (en) | 1988-02-25 | 1992-01-14 | Immunex Corporation | Interleukin-1 receptors |
| USRE35450E (en) | 1987-11-25 | 1997-02-11 | Immunex Corporation | Soluble human interleukin-1 receptors, compositions and method of use |
| DE3817955A1 (en) | 1988-05-27 | 1989-11-30 | Hoechst Ag | MEDICINAL PRODUCT CONTAINING TNF INHIBITOR |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
| US5064837A (en)* | 1989-11-13 | 1991-11-12 | Schering Corporation | 3-substituted-1-aryl-2(h)-quinolones and their pharmaceutical compositions |
| AU649245B2 (en)* | 1990-04-02 | 1994-05-19 | Amgen, Inc. | Methods for treating interleukin-1 mediated diseases |
| AU7775991A (en) | 1990-04-04 | 1991-10-30 | Immunex Corporation | Interleukin 1beta protease |
| US5162361A (en)* | 1990-04-10 | 1992-11-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method of treating diseases associated with elevated levels of interleukin 1 |
| WO1991017184A1 (en) | 1990-04-27 | 1991-11-14 | The Upjohn Company | Modified interleukin-1 inhibitors |
| US5872095A (en)* | 1990-05-01 | 1999-02-16 | Chiron Corporation | IL-1 receptor antagonists medicaments |
| US5350683A (en)* | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
| DK0835939T3 (en) | 1990-06-28 | 2006-03-13 | Sanofi Aventis Deutschland | Fusion proteins with proportions of immunoglobulin, their preparation and use |
| SG86971A1 (en)* | 1990-11-30 | 2002-03-19 | Teijin Ltd | 2-arylthiazole derivatives and pharmaceutical composition thereof |
| AU9106491A (en)* | 1991-01-17 | 1992-08-27 | Upjohn Company, The | Method of preventing and treating insulin dependent diabetes mellitus |
| DK0575545T3 (en) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylation of polypeptides |
| US5656272A (en)* | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
| RU2206611C2 (en) | 1991-08-30 | 2003-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | DNA FRAGMENT, PLASMID VECTOR, METHOD FOR PREPARING POLYPEPTIDE AND POLYPEPTIDE ELICITING IL-1β PROTEASE ACTIVITY |
| US5770401A (en)* | 1991-10-15 | 1998-06-23 | Mullarkey; Michael F. | Methods and compositions for treating allergic reactions |
| GB9123326D0 (en) | 1991-11-04 | 1991-12-18 | Sandoz Ltd | Improvements in or relating to organic compounds |
| EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
| AU3479593A (en) | 1992-01-31 | 1993-09-01 | Merck & Co., Inc. | Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme |
| CA2129976C (en) | 1992-02-21 | 2002-09-17 | Kevin T. Chapman | Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme |
| US5547979A (en) | 1992-03-30 | 1996-08-20 | Smithkline Beecham | TNF inhibition |
| WO1993021946A1 (en)* | 1992-04-30 | 1993-11-11 | Synergen, Inc. | Methods for treating interleukin-1 and tumor necrosis factor mediated diseases |
| GB9223904D0 (en) | 1992-11-13 | 1993-01-06 | British Bio Technology | Inhibition of cytokine production |
| US5521315A (en)* | 1993-01-12 | 1996-05-28 | Cell Therapeutics, Inc. | Olefin substituted long chain compounds |
| ATE163412T1 (en) | 1993-06-08 | 1998-03-15 | Sanofi Sa | PYRIDAZINE AS INTERLEUKIN-1-BETA CONVERSION ENZYME INHIBITORS |
| GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
| US5508300A (en) | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
| ATE165817T1 (en) | 1994-01-20 | 1998-05-15 | British Biotech Pharm | METALLOPROTEINASE INHIBITORS |
| AU703451B2 (en) | 1994-03-31 | 1999-03-25 | Vertex Pharmaceuticals Incorporated | N-(pyrimidinyl)-aspartic acid analogs as interleukin-1beta converting enzyme inhibitors |
| US5519000A (en) | 1994-04-01 | 1996-05-21 | Centecor, Inc. | Tumor necrosis factor inhibitors |
| US5552400A (en) | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| GB9412672D0 (en) | 1994-06-23 | 1994-08-10 | Celltech Ltd | Chemical compounds |
| CA2192821A1 (en)* | 1994-06-24 | 1996-01-04 | Wayne R. Gombotz | Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
| GB2291422A (en) | 1994-07-18 | 1996-01-24 | Fujisawa Pharmaceutical Co | 4-phenyl-pyrido[2,3-b]pyrazin-4-ones |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| IT1269989B (en) | 1994-09-21 | 1997-04-16 | Dompe Spa | IL-1 RECEPTOR ANTAGONISTS WITH INCREASED INHIBITORY ACTIVITY |
| US5656624A (en)* | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| JP3053222B2 (en) | 1995-04-20 | 2000-06-19 | ファイザー・インコーポレーテッド | Arylsulfonylhydroxamic acid derivatives as MMP and TNF inhibitors |
| US5641751A (en) | 1995-05-01 | 1997-06-24 | Centocor, Inc. | Tumor necrosis factor inhibitors |
| US5753628A (en) | 1995-06-07 | 1998-05-19 | Centocor, Inc. | Peptide inhibitors of TNF containing predominantly D-amino acids |
| US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| JP4344404B2 (en)* | 1996-02-09 | 2009-10-14 | アムジェン インコーポレイテッド | Composition comprising interleukin-1 inhibitor and controlled release polymer |
| US5776731A (en)* | 1996-02-21 | 1998-07-07 | Immunex Corporation | DNA encoding type-I interleukin-I receptor-like protein designated 2F1 |
| CA2248551A1 (en)* | 1996-03-15 | 1997-09-18 | The General Hospital Corporation | Programmed cell death and interleukin-1.beta. |
| US5874592A (en)* | 1996-04-03 | 1999-02-23 | Kyowa Hakko Kogyo Co., Ltd. | Physiologically active substance EI-2128-1 |
| GB9607120D0 (en) | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
| BR9709105A (en) | 1996-05-20 | 1999-08-03 | Darwin Discovery Ltd | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors |
| DE69700616T2 (en)* | 1996-07-02 | 2000-03-16 | Nisshin Flour Milling Co., Ltd. | Imide derivatives |
| US6054559A (en)* | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
| US5883131A (en) | 1997-07-09 | 1999-03-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| AU9013998A (en) | 1997-07-21 | 1999-02-10 | Zymogenetics Inc. | Tumor necrosis factor receptor ztnfr-5 |
| JP2001517666A (en) | 1997-09-23 | 2001-10-09 | 藤沢薬品工業株式会社 | Thiazole derivatives |
| US6020339A (en) | 1997-10-03 | 2000-02-01 | Merck & Co., Inc. | Aryl furan derivatives as PDE IV inhibitors |
| US6080580A (en) | 1998-10-05 | 2000-06-27 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression |
| US6306978B1 (en)* | 1999-02-05 | 2001-10-23 | General Electric Company | Capping of polyphenylene ether resin |
| US6086095A (en) | 1999-07-30 | 2000-07-11 | Milliken & Company | Airbag cushion exhibiting low seam and fabric usage and simultaneously high available inflation volume |
| US7572770B2 (en)* | 2002-06-27 | 2009-08-11 | University Of Zurich | Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| Publication number | Publication date |
|---|---|
| WO2001087328A2 (en) | 2001-11-22 |
| WO2001087328A3 (en) | 2002-08-22 |
| EP2241328A1 (en) | 2010-10-20 |
| US20010053764A1 (en) | 2001-12-20 |
| EP1712239A2 (en) | 2006-10-18 |
| EP2329842A3 (en) | 2011-07-27 |
| EP1712239A3 (en) | 2007-08-22 |
| EP1282435A2 (en) | 2003-02-12 |
| EP2329842A2 (en) | 2011-06-08 |
| US20090022733A1 (en) | 2009-01-22 |
| US20040023869A1 (en) | 2004-02-05 |
| Publication | Publication Date | Title |
|---|---|---|
| AU2001259758A1 (en) | Interleukin-1 inhibitors in the treatment of diseases | |
| PL374118A1 (en) | Interleukin-1 receptors in the treatment of diseases | |
| AU2000260550A1 (en) | Treatment of skin damage using polyenylphosphatidylcholine | |
| IL155092A0 (en) | Compounds useful in the treatment of inflammatory diseases | |
| AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
| AU2002248269A1 (en) | Use of p38 inhibitors for the treatment of inflammation-enhanced cough | |
| AU2002247208A1 (en) | Selective pde3b inhibitors and use of the same in therapy | |
| AU2001245987A1 (en) | Compositions and methods for gene therapy | |
| AU2002210385A1 (en) | Furazanyl-triazole derivates for the treatment of diseases | |
| AU2002233928A1 (en) | Cycloalkylfused (g)-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases | |
| AUPR074500A0 (en) | Treatment of t cell disorders | |
| AU2002241661A1 (en) | Multifunctional protease inhibitors and their use in treatment of disease | |
| AU2001260834A1 (en) | The treatment of herpes | |
| AU2001236713A1 (en) | Methods for treatment of lysosomal storage diseases | |
| AU2001265186A1 (en) | Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions | |
| IL155174A0 (en) | Methods and compositions for the treatment of inflammatory diseases | |
| AU2003206945A1 (en) | Use of proteinase inhibitors in the treatment of autoimmune diseases | |
| AU2001292818A1 (en) | Use of transcription factors for treating inflammation and other diseases | |
| AU2003244455A1 (en) | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases | |
| AU2002210763A1 (en) | Use of 1-ebio in the treatment of bipolar disorders | |
| AU2001255168A1 (en) | Compositions and methods for the treatment of immune related diseases | |
| AU2003240446A1 (en) | Use of mob-5 in pain | |
| AU2001253560A1 (en) | Methods of treatment | |
| AU2001262520A1 (en) | Combined preparation for the treatment of neoplasic diseases | |
| AU2001275165A1 (en) | Treatment of side effects associated with alcohol consumption |